M&A Deal Summary

ProPhase Labs Acquires Clinical Laboratory Improvement Amendments

On October 23, 2020, ProPhase Labs acquired life science company Clinical Laboratory Improvement Amendments

Acquisition Highlights
  • This is ProPhase Labs’ 1st transaction in the Life Science sector.
  • This is ProPhase Labs’ 1st transaction in the United States.
  • This is ProPhase Labs’ 1st transaction in New Jersey.

M&A Deal Summary
Date 2020-10-23
Target Clinical Laboratory Improvement Amendments
Sector Life Science
Buyer(s) ProPhase Labs
Deal Type Add-on Acquisition

Target

Clinical Laboratory Improvement Amendments

Old Bridge, New Jersey, United States
Confucius Plaza Medical Laboratory Corp. is a full service clinical and molecular lab that provides a wide range of testing for diagnosis, screening and evaluation of diseases, including COVID-19 viral and antibody tests. Confucius Plaza Medical Laboratory is based in Old Bridge, New Jersey.

Search 193,240 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

ProPhase Labs

Garden City, Pennsylvania, United States

website

Category Company
Founded 1989
Sector Life Science
Employees95
Revenue 79M USD (2021)
DESCRIPTION

ProPhase Labs is a diversified natural health medical science company. It develops and markets clinically proven remedies including the highly effective Cold-EEZE® and Kids-EEZE® product lines. ProPhase Labs was founded in 1989 and is based in Garden City, New York.

DEAL STATS #
Overall 1 of 2
Sector (Life Science) 1 of 2
Type (Add-on Acquisition) 1 of 2
State (New Jersey) 1 of 1
Country (United States) 1 of 2
Year (2020) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2017-01-09 Cold-EEZE

Doylestown, Pennsylvania, United States

Cold-EEZE is a cold remedy zinc gluconate lozenges are clinically proven to significantly reduce the duration of the common cold.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2021-08-11 Nebula Genomics

San Francisco, California, United States

Nebula Genomics provides consumers access to affordable and secure whole-genome sequencing via its online portal. Nebula’s solution is powered by the innovations of George Church, Ph.D. Dr. Church has pioneered the development of multiple DNA sequencing methods, including molecular multiplexing approaches that enable next-generation DNA sequencing (NGS) as well as nanopore sequencing. Nebula Genomics was founded in 2016 and is based in San Francisco, California.

Buy $15M
Mergr

Product

Company

Legal